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Abstract: Aortic valve stenosis in children is a congenital heart defect that causes fixed form of
hemodynamically significant left ventricular outflow tract obstruction with progressive course.
Neonates and young infants who have aortic valve stenosis, usually develop congestive heart failure.
Children and adolescents who have aortic valve stenosis, are mostly asymptomatic, although they
may carry a small but significant risk of sudden death. Transcatheter or surgical intervention is
indicated for symptomatic patients or those with moderate to severe left ventricular outflow tract
obstruction. Many may need reintervention.
Keywords: congenital aortic stenosis; balloon aortic valvuloplasty; surgical aortic valvuloplasty;
congenital heart disease
1. Introduction
Valvular aortic stenosis (VAS) accounts for approximately 3–6% of congenital heart defects [1].
The VAS is almost always congenital in origin in pediatric patient. It occurs more frequently in males
than in females, by a ratio between 3:1 and 5:1. Associated congenital heart diseases, including patent
ductus arteriosus, coarctation of aorta and ventricular septal defects, are present in 15–20% of patients
who have VAS.
2. Anatomy and Pathology
The functional unit of a normal aortic root is the three aortic sinuses of Valsalva that are
formed by an expansion of the aortic wall and the semilunar attachment of its corresponding leaflet,
which create three pocket-like spaces. They are separated by commissural spaces and interleaflet
triangles, the trigones [2,3]. The sum of the areas of the leaflets is greater than the cross-sectional area
of the aortic root that along with tissue pliability allows for a competent closure during diastole and
unobstructed valve opening during systole.
Congenital VAS displays several morphologic types of abnormal valves: unicuspid, bicuspid,
tricuspid and quadricuspid [4]. The unicuspid aortic valve, most frequently seen in critical VAS,
has either an eccentric orifice with one patent commissure or a central orifice with no commissure [2,4].
The single, thickened leaflet has a limited flap-valve type of opening during systole, which causes
marked flow obstruction and does not lend itself well to balloon valvuloplasty [3]. The bicuspid aortic
valve is the most common congenital heart disease with a prevalence of approximately 2% of the
population [1]. From surgical point of view, there can be three types of morphological bicuspid aortic
valve depending on number of raphe: type 0 (no raphe in the valve), type 1 (only one raphe in the
valve) and type 2 (two raphes in the valve) [5]. The most common type is type 1, which accounts
for about 90% of the patients with bicuspid aortic valve [6]. The two leaflets are arranged either
in an anteroposterior orientation (approximately 80% of the cases) or a right–left orientation [2,7].
Valvular aortic stenosis results if the lengths of the free edges of the leaflets are less than those of the
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attachments to the sinuses, if the leaflets are dysplastic or if commissures are fused. The majority of
bicuspid aortic valves develop degenerative changes with aging. Valvular aortic stenoses in many
fetuses and infants are associated with the inadequate growth of left heart structures, left ventricular
endocardial fibroelastosis and dysfunction, which constitute a distinct pathological entity. Children
born with a bicuspid aortic valve have a larger ascending aorta that increases in size at a higher rate
than that of matched controls with a tricuspid aortic valve [8]. There are six types of dilated aorta
in children that are associated with the bicuspid aortic valve which include the normal shape (S1),
the enlarged ascending aorta (S2), the effacement of the sinotubular ridge (S3), the Marfan-like (S4),
the enlarged sinus of Valsalva and ascending aorta (S5), the normal annulus and proximal sinus of
Valsalva, enlarged distal sinus of Valsalva, sinotubular ridge and ascending aorta (S6). S2 and S3
occur more than other types. The prevalence of dilatation at the level of the tubular ascending aorta
increases with age and has been reported to be 56%, in younger than 30 years to 74%, in older than
30 years of age [9]. Both the bicuspid aortic valve and the development of bicuspid aortopathy have
been attributed to genetic basis. Bicuspid aortic valve is an autosomal-dominant disease with a highly
heritable trait. Autosomal dominant, X-linked and familial modes of inheritance for aortopathy have
been reported. Abnormal migration of neural-crest cells probably is a common pathway that results in
a bicuspid aortic valve and aortopathy [10].
Recently, the genetic basis for the pathogenesis of VAS has been identified. A study identified
significantly altered CpG methylation at 59 sites in 52 genes in patients with VAS [11]. These genes are
involved in positive regulation of receptor-mediated endocytosis. A significant epigenetic change in
the APOA5 and PCSK9 genes known to be involved in VAS was also observed. Thus, CpG methylation
can be used as molecular screening markers for the development of VAS. Some novel biomarkers that
are currently being investigated such as galectin-3, growth differentiation factor-15 and micro RNAs
have the potential for diagnostic and prognostic biomarkers use in VAS [12].
3. Pathophysiology
The pathophysiology of VAS is determined by the age of the patient at onset, its severity and any
associated cardiac abnormalities.
Although the development of VAS is mostly completed by the first trimester, it may evolve
throughout the gestation. Fetuses who develop severe aortic stenosis by the second trimester
demonstrate failure of growth of the aortic root and left ventricle cavity [13]. Reduced growth rate of
other left heart structures predict the development of hypoplastic left heart syndrome (HLHS) [13,14].
However, in isolated VAS that has associated unrestrictive foramen ovale and ductus arteriosus,
the right ventricle usually compensates for the decreased left ventricular output. Valvular aortic
stenosis in symptomatic neonates and young infants is usually critical in nature. The left ventricle
(LV) may be limited in its ability to match cardiac output to postnatal demand because of increased
afterload mismatch resulting from removal of the low-resistance placental circulation after birth. With
closure of the ductus arteriosus, systemic cardiac output diminishes and congestive heart failure
develops, the timing of which varies among neonates. The VAS in children and adolescents is the
result of a relatively unchanged effective valve orifice with growth. The increased LV mass induced by
increased wall stress initially overcompensates for pressure overload. The initial hemodynamics are
characterized by normal or supranormal ejection fraction and cardiac output both at rest and during
exercise [15]. Later, with progressive stenosis, the LV hypertrophy develops that causes diastolic
dysfunction and increased myocardial oxygen consumption if unmatched by coronary blood flow,
which may lead to myocardial ischemia and fibrosis. The diastolic dysfunction leads to increased
reliance on atrial contribution to LV filling. These pathological developments may lead to stage C
heart failure.
The pathogenesis of progression of stenosis at valvular level is complex. The aortic valve
leaflets of VAS endure a complex mechanical environment, including leaflet stretch, fluid shear stress,
bending stresses and pressure forces. Altered mechanical stimuli on the leaflets lead to valvular
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endothelial dysfunction, deposition of oxidized low-density lipoprotein, which may trigger infiltration
of macrophages and other cytokines, resulting in inflammation. The areas of inflammation develop
fibrosis, followed by leaflet thickening and finally calcification [16]. This natural progression leads to
further development of stenosis and increased afterload to the LV. Although not a common feature
in pediatric age, aortic aneurysm formation and aortic dissection are the two major complications of
bicuspid aortopathy, mostly encountered beyond pediatric age. The aortic diameter at baseline is an
important predictor of aortic expansion [17]. A recent study involving more than 400 consecutive
patients with a bicuspid aortic valve showed that an aortic diameter of 40 mm or more at baseline
independently predicted the subsequent development of an aneurysm, as compared with a baseline
diameter of less than 40 mm in older children and adults [18]. Other predictors of progression of
bicuspid aortopathy include elevated systolic blood pressure, aortic valve stenosis or regurgitation and
morphologic features of the valve (R-L fusion pattern) [19]. However, the incidence of aortic dissection
is low, an average of 0.1% per patient year of follow-up reported in a study of adult patients with
bicuspid aortic valve [20].
4. Clinical Presentations
Clinical findings depend upon the age of the patient at the presentation, severity of the VAS and
the presence of associated cardiac lesions.
In fetuses, VAS is diagnosed on fetal echocardiography as thicken and/or doming aortic valve
with increased Doppler flow velocity >1 m/s. The VAS is a progressive lesion. Some fetal VAS may
progress to HLHS manifested by the development of reversed flow in the transverse aortic arch and
foramen ovale, monophasic mitral inflow and LV dysfunction in the second trimester [21]. Additionally,
reduced growth rate of the left heart structures also predicts the development of HLHS [13,14].
The neonatal and well-baby check-ups perform poorly as screening tests for severe VAS.
The majority of infants with severe VAS present with progressive congestive heart failure by 2 months
of age. They appear pale, mottled, hypotensive and dyspneic. A normal first heart sound, an ejection
click, and a gallop are present in approximately 50% of those affected. An ejection systolic murmur of
variable intensity is present along the mid-left and right upper sternal borders, radiating to the carotid
arteries. The presence of hypoxia (PaO2 30–40 mmHg (4–5.3 kPa)) and metabolic acidosis indicates the
need for immediate medical treatment and intervention.
The older children and adolescents with VAS are usually asymptomatic. Symptoms of
dyspnea, angina or syncope, particularly on exercise are usually present in 10% of older children.
The development of such symptoms deserve prompt and thorough evaluation anytime because of the
risk of sudden death noted in 1–10% in those between ages of 5 and 15 years of age who have moderate
to severe VAS [22].
The characteristic physical findings, such as arterial pulsus parvus et tardus (small amplitude
and slow-rising pulse), carotid shudder and prominent jugular venous a wave, which are described in
adults with VAS, are not uniformly present in children. A precordial systolic thrill over the base of the
heart is present in >65% of patients with more than mild VAS. A narrowly split, single or a paradoxically
split second heart sound along with a fourth heart sound indicates severe VAS. An ejection click is
present in pliable and absent in immobile aortic valve. It is unaffected by respiration and absent in
severe VAS. The characteristic low-pitched crescendo–decrescendo systolic murmur of VAS, which
start just after the ejection click, is best heard at the base of the heart. It radiates to the carotid arteries.
The murmur of VAS increases in intensity by maneuvers that increase stroke volume, such as isotonic
exercise and premature ventricular contractions.
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5. Diagnostic Techniques
5.1. Lesion Morphology
Echocardiography is the diagnostic tool of choice in pediatric patients to evaluate valve
morphology, lesion severity and LV adequacy and function. Two-dimensional and three-dimensional
echocardiography demonstrate the valve morphology, aortic root dimensions, the presence of
commissural fusion or raphes and the position and orientation of the valve orifice. The “surgeon’s
view” (Figure 1) by three-dimensional echocardiography delineate the surgical anatomy and anatomic
orifice area of the valve that can help decide the type of valve surgery or intervention. Bicuspid
aortic valves due to right and left coronary leaflet cusp fusion have less risk whereas those with
other types of fusion of leaflets have more risk of the occurrence of VAS and associated aortopathy.
Echocardiography provides accurate morphology and aids in the classification of the types of aortic
valve lesion [23]. Echocardiography also provides assessment of left ventricular hypertrophy and
function and associated cardiac lesions.
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Figure 1. Valvular aortic stenosis with a bic s i alve. f ll volume rendered three-dime sional
echocardiographic “surgeon’s view” of a bicuspid aortic valve in systole showing fused right (RCC)
and noncoronary (NCC) cusps with prominent ridge, a smaller left coronary cusp (LCC) (lower to the
orifice) and an eccentric elliptical restricted orifice (in light blue color).
5.2. Lesion Severity
A quantitative assessment of the severity of the valve stenosis that determines the need and timing
for intervention, is estimated by aortic valve pressure gradient in pediatric patients. The transvalvular
pressure gradient (P) calculated from peak instantaneous Doppler echocardiographic velocity (V)
measurements obtained from multiple directions and using a simplified Bernoulli equation [24] is
usually used to assess the severity of VAS in this age group:
P = 4V2 (1)
Based on the natural history data, in clinical pediatric practice, a catheter-measured peak-to-peak
LV to aortic pressure gradient is the accepted reference for decision making to perform catheter or
surgical interventions in the pediatric population [22]. However, the Doppler peak instantaneous
pressure gradient overestimates the catheter-measured peak-to-peak pressure gradient. Others and
we have shown that the discrepancy b tween the Do pler peak instantaneous pr ssure gradient and
catheter measu ed peak-to-p ak pressure gradient mostly occurs because Doppler gradient does not
take in ac ount the downstream pressure recovery phen menon [25]. If the recovered pressure is
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deducted from the Doppler peak instantaneous pressure gradient, the net pressure reliably predicts the
catheter peak-to-peak gradient [25,26]. The recovered pressure can be derived by echocardiography:
RP = 4V2 × 2AVA/AOA × ((1 − AVA)/AOA)) (2)
where RP is recovered pressure, AVA is aortic valve area (discussed in next section) and AOA is
ascending aorta cross-sectional area [25]. The Doppler mean gradient has also been used as an estimate
of the severity of VAS, because it is directly comparable to the catheter-measured mean pressure
gradient. In isolated VAS, a resting peak-to-peak valve gradient (by catheter) of ≥50 mm Hg is class I
indication for aortic valvuloplasty in children [27].
Because the pressure gradient, which is calculated from the measured velocity, may not correctly
assess the severity of aortic stenosis in low-flow states, aortic valve area (AVA) is employed to assess
accurately the severity of the lesion. It is calculated by the continuity equation. The AVA obtained by the
continuity equation using echocardiography correlates closely to but often underestimates, that obtained
by cardiac catheterization using the Gorlin formula [28]. In clinical pediatric practice, pitfalls in
calculating left ventricular outflow tract (LVOT) area due to error in measurements of LVOT diameter
make the continuity equation a less used method to evaluate the severity of VAS. Other hemodynamic
measurements of the severity of VAS such as energy-loss index, AV resistance, valvulo-arterial
impedance and LV stroke loss may also be calculated from the data acquired by echocardiography and
catheterization [29]. However, low-flow/low-gradient and high arterial impedance are not seen in the
pediatric patients and their hemodynamic measurements are not discussed here.
5.3. Assessment of the Adequacy of the Left Heart Structures and Function
Because adequacy of left heart structures and function influences the outcome of intervention in
infants with VAS, many echocardiographic morphometric parameters and hemodynamic variables
of the left heart have been used to determine whether relieving the LVOT obstruction will achieve
a two-ventricle repair or whether a staged single-ventricle repair (the Norwood procedure) should be
considered [30,31].
The following morphometric measurements of the left heart structures favor two-ventricle repair:
• indexed aortic annulus of ≥3.0 cm/m2 and indexed aortic root of ≥3.5 cm/m2;
• indexed mitral valve area of ≥4.75 cm2/m2;
• a ratio of the long axis of the left ventricle to that of the heart of ≥0.8; and
• left ventricular cross-sectional area of ≥2.0 cm2.
On the basis of some of the morphometric parameters, Rhodes et al [30]. developed a predictive
equation for survival:
Discrimination Score = 14.0(body surface area) + 0.943(indexed aortic root)
+ 4.78(LAR) + 0.157(mitral valve area) − 12.03 (3)
where LAR is the ratio of the long axis of the left ventricle to that of the heart. A discrimination score
of less than −0.35 is predictive of poor outcome after two-ventricle repair.
5.4. Cardiac Catheterization
Cardiac catheterization for the diagnostic evaluation of VAS severity is indicated in children and
adolescents with Doppler mean gradient >30 mm Hg or the peak gradient >50 mm Hg if [32]:
• they are symptomatic with angina, syncope or dyspnea on exertion (Class I);
• there is a discrepancy between clinical and noninvasive findings regarding severity of VAS
(Class I);
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• they are asymptomatic but have developed T-wave inversion over left precordium during exercise
test (Class I);
• they are asymptomatic but are interested in athletic participation (Class I1); and
• there is several levels of LVOT obstruction in series that is likely to influence the therapeutic
option or if interventional balloon aortic valvuloplasty is planned.
5.5. Electrocardiography
Electrocardiographic changes are neither diagnostic nor sensitive to the degree of severity of VAS
in general. However, left ventricular hypertrophy with strain and ST-segment depression of 2 mm or
more in the left precordial leads is a relatively sensitive indicator of severe VAS.
There is a greater incidence of serious ventricular arrhythmias and sudden death in children and
adolescents who have relatively long-standing moderate to severe VAS than in the normal population.
An yearly ambulatory ECG monitoring is recommended in asymptomatic children and adolescents
with Doppler mean gradient greater than 30 mm Hg or peak gradient greater than 50 mm Hg (Class I
indication) [32].
5.6. Exercise Testing
Exercise testing is contraindicated in symptomatic patients. Graded exercise testing is a reasonable
diagnostic evaluation in the children and adolescents with VAS who have a Doppler mean gradient
>30 mm Hg or a peak gradient >50 mm Hg or if they are interested in athletic participation (Class II
indication) [32]. Most patients who have moderate VAS but are asymptomatic have a blunted increase
in systolic blood pressure (<25 mm Hg) and cardiac index during exercise [33,34]. The presence of
serious arrhythmias and the extent of ST-segment depression, are indicative of myocardial ischemia
and indications for therapeutic intervention [33].
6. Natural History
Congenital VAS is a progressive disorder. In the Second Natural History Study, the catheter
measured peak-to-peak systolic gradient was found to be the most reliable indicator of the clinical
course [22]. Beyond infancy, patients with a catheter-measured peak pressure gradient of less than
25mmHg have ~20% chance of requiring a valvotomy and those with a gradient of 25–49 mm Hg
have ~40% chance. Patients who have a gradient of 50 mm Hg or more have a 70% chance of
requiring an intervention for relief of obstruction, which, if unattended, may put them at risk of serious
ventricular arrhythmia, sudden death and other morbid events at a rate of 1–1.5% per year. As with
many congenital heart diseases, bacterial endocarditis is a potential complication of VAS. In the Second
Natural History Study, the incidence of bacterial endocarditis was 27.1 per 10,000 person-years [35].
7. Management
The management of VAS is determined by the age of the patient at presentation, the severity of
the obstruction and adequacy of left heart structures. The current therapeutic intervention options to
relieve LVOT obstruction are percutaneous balloon aortic valvoplasty, surgical aortic valvotomy and
valve replacement, all of which are intended for biventricular repair. Norwood procedure is employed
for single ventricular repair.
7.1. Balloon Aortic Valvuloplasty
The balloon catheter is advanced retrogradely, usually via percutaneous femoral artery puncture
or the umbilical artery (in the neonates), or progradely via the patent foramen ovale and is
positioned across the stenotic valve over an extra-stiff exchange length guidewire. Recently, real-time
3D echocardiographic-fluoroscopic fusion imaging has allowed more efficient navigation, better
visualization of the anatomic landmarks and catheter position, and more effective intervention by
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balloon valvuloplasty [36]. The recommended balloon:annulus ratio is 0.8–1.0. The radial dilating force
exerted by the inflation of the balloon usually tears the weakest part of the valve. In bicuspid aortic
valve, the balloon dilatation tears the fused commissures with adequate relief of obstruction and some
valvular insufficiency. In unicuspid valve, however, balloon dilatation tends to split the leaflet opposite
the patent commissure with only partial relief of obstruction and significant valvular insufficiency.
The risk of increased aortic regurgitation following balloon valvuloplasty may be significant in
those who have aortic valve annulus eccentricity, which is often innate in infants and children with
VAS. Measurements of different annular sizes in parasternal long axis and short axis views of 2D
echo images could provide the sizes of the aortic valve annuli to help choose the appropriate size
balloon catheter. It is suggested that aortic balloon valvuloplasty might help in achieving therapeutic
effects when taking the different annular size into account [37]. In our experience, cardiac MRI gives
an accurate way to quantify aortic regurgitation, LV volumes and function. This gives a better basis for
making decision as per ACC/AHA guidelines for the need and timing of intervention in mixed lesion
of VAS and aortic regurgitation. Others and we have also found circumferential as well as longitudinal
strains by speckle tracking strain echocardiography as an adjunct modality for the assessment of LV
function in asymptomatic patients with hemodynamically significant mixed lesions [38].
Immediate, Intermediate and Long-Term Results
Immediate reduction in peak pressure gradient across the aortic valve is observed in the
majority of patients after balloon aortic valvuloplasty. Data from Valvuloplasty and Angioplasty of
Congenital Anomalies Registry, revealed an average reduction in transvalvular gradients of 60% and
procedure-related mortality of 1.9% [39]. In a single-institution study of patients in the age group
1 month to 20 years, mid-term results showed an 8-year actuarial survival of 95%, freedom from
operation of 70% and freedom from intervention of 50% [40]. In an intermediate-term follow-up
in a series of neonatal balloon valvuloplasties, mortality was 12% and probability of survival and
freedom from reintervention at 8 years were 88% and 64%, respectively [41]. Predictors of restenosis
are age 3 months or less and an immediate post-valvuloplasty peak gradient 30 mm Hg or more [39,42].
Long-term follow-up data suggest that the incidence of residual obstruction is low but nearly 25% of
the patients develop restenosis, requiring reintervention [26]. Degree of immediate post-valvuloplasty
aortic insufficiency is predictive of late onset of aortic insufficiency [42,43]. Thus, the immediate
post-valvuloplasty incompetence grade and transvalvar gradient are the predictors of intermediate
term re-intervention.
In one of the longest (range 0.1–23.6 years) and the largest cohort (509 children with VAS) post
balloon valvuloplasty follow-ups; survival free from any aortic valve reintervention was 89 ± 1%
at 1 year, 72 ± 2% at 5 years, 54 ± 3% at 10 years and 27 ± 3% at 20 years. Freedom from aortic
valve replacement was 90 ± 2% at 5 years, 79 ± 3% at 10 years and 53 ± 4% at 20 years. The lower
post-dilation VAS gradient and lower grade of post-dilation aortic regurgitation were associated with
longer freedom from aortic valve replacement but age, era and pre-dilation AS severity were not [44].
Thus, transcatheter aortic valvuloplasty is effective for relief of congenital VAS but there are steady
long-term hazards for surgical aortic valve reintervention and replacement that are independent of age
at initial intervention or VAS severity.
7.2. Surgery
Surgical valvotomy is usually performed under cardiopulmonary bypass with cardioplegic and
topical hypothermic myocardial protection. Through a transverse aortotomy, a commissurotomy and
the removal of fibrous excrescence and nodules from the aortic leaflets are performed. In patients who
have an essentially uncorrectable valve, a small aortic annulus or recurrent stenosis with significant
aortic regurgitation, an aortic valve replacement with a prosthetic valve or an aortic valve allograft
may be performed in standard fashion. Because of its proven viability, the potential for growth and
the lack of need for anticoagulation, pulmonary autograft (the Ross procedure) is often used for
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valve replacement in many centers, although it involves a previously healthy right outflow tract and
predisposes it to two valve disease and further reoperations. Further controversy about the Ross
operation exists regarding late dilatation of the pulmonary autograft and regurgitation of the neo-aortic
valve when the procedure is performed in the full root technique. Autograft reinforcement with
a prosthetic Dacron graft may be especially useful in situations known for late autograft dilatation,
namely, bicuspid aortic valve, predominant aortic insufficiency and ascending aortic enlargement.
The mid- to long-term results after such adjunct technique demonstrated no late aortic root enlargement
and a well-functioning autograft valve without significant aortic regurgitation [45].
Patients who have been diagnosed with bicuspid aortic valve with stenosis manifest morphological
changes in valve including annular eccentricity, asymmetrical calcified leaflet, presenting different
sizes of leaflets. Such patients with substantial aortic valve dysfunction, aortic root dilatation and
aortic dilation >4.5 cm are likely to need replacement of the aortic valve, aortic root and ascending.
In patients with isolated involvement of the aortic root, surgical options may include aortic valve and
aortic-root replacement with the use of a composite valve conduit (Bentall procedure) that usually
have excellent outcomes in older children and adults [46].
Immediate and Long-Term Surgical Results
Compared to previous surgical era when surgical valvotomy in neonates with critical carried
~50% morality [47], the surgical mortality in the neonates with isolated critical VAS has reduced to less
than 8% and 10-year survival thereafter has improved up to 100% with proper patient selection [48].
7.3. Balloon Valvuloplasty vs. Surgical Valvuloplasty for Valvular Aortic Stenosis (VAS)
Controversy exists regarding the catheter intervention versus surgical approach as the best
treatment for neonates and infants with congenital VAS. In an Australian study of 123 consecutive
neonates and infants who underwent relief of congenital VAS either by balloon valvuloplasty or surgical
valvuloplasty, 20-year survival was 80 ± 7% and freedom from re-intervention was 40 ± 6%. Having the
relief of stenosis by balloon valvuloplasty and undergoing initial treatment as a neonate were predictive
of re-intervention. Freedom from re-intervention at 5 years was 27% after balloon valvuloplasty versus
65% after surgery. Thus, after surgery, a higher proportion of patients remain free of re-intervention
than after interventional catheterization and the relief of their stenosis lasted longer [49]. Similar
conclusion was drawn in another study of children who underwent surgical valvuloplasty (n = 89) and
balloon valvuloplasty (n = 69) in the same era from an institutional experience. Balloon valvuloplasty
yielded less gradient reduction, more postprocedural aortic regurgitation and a shorter interval between
initial and subsequent reintervention than did the surgical valvuloplasty [50]. In a contemporary
systematic review and meta-analysis to compare survival and outcomes in children with congenital
VAS of 20 studies, there was no difference between surgical valvuloplasty and balloon valvuloplasty in
hospital mortality (OR = 0.98, 95% CI 0.5–2.0, P = 0.27, I2 = 22%) or frequency of at least moderate
aortic regurgitation at discharge (OR = 0.58, 95% CI 0.3–1.3, P = 0.09, I2 = 54%). Kaplan–Meier analysis
showed no difference in long-term survival or freedom from aortic valve replacement but significantly
more reintervention in the balloon valvuloplasty group (10-year freedom from reintervention of 46%
(95% CI 40–52) for BAV versus 73% (95% CI 68–77) for surgical valvuloplasty, P < 0.001) [51]. Although
higher rates of reintervention suggest improved outcomes with surgical valvuloplasty, there were more
morbidity and longer hospital stay involved in surgical valvuloplasty than in balloon valvuloplasty.
7.4. Specific Considerations for the Management of the Infants with Critical VAS
Neonates who have critical VAS with ductus-dependent systemic circulation, present with rapidly
progressive congestive heart failure as the ductus arteriosus closes. They require aggressive treatment
with prostaglandin E1 infusion, inotropic support, diuretics, correction of metabolic acidosis and
mechanical ventilation to improve the systemic perfusion. To determine the therapeutic option for
single ventricle versus two-ventricle repair, the Rhode’s equation can be used. The Congenital Heart
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Surgeons Society, after a large multicenter prospective study, produced a multiple linear regression
equation that predicts the magnitude and the direction of the optimum pathway for a 5-year survival
benefit of Norwood (staged single-ventricle repair) compared with biventricular repair [52]:
Survival benefit = intercept + b1 (age at entry) + b2 (Z score of aortic valve at sinuses) +
b3 (grade of endocardial fibroelastosis) + b4 (ascending aorta diameter) + b5 (presence of
moderate or severe tricuspid regurgitation) + b6 (Z score of the left ventricular length).
(4)
Using their appropriate transformation factors, a positive number from the equation would
favor a Norwood procedure and a negative number could favor a biventricular repair. For those
selected for biventricular repair, surgical aortic valvotomy and transcatheter balloon dilatation have
similar outcomes but with greater likelihood of significant aortic regurgitation with the latter and
of residual stenosis with the former [53]. Multiple centers as well as our preference is for balloon
aortic valvuloplasty [54]. Multiple routes can be used for balloon valvuloplasty including anterograde,
transumbilical venous route and transumbilical arterial route and carotid artery cut-down [54].
7.5. Specific Considerations for the Management of Children and Adolescents with VAS
7.5.1. Indications for Intervention
Because of good results comparable to those obtained surgically as well as due to little morbidity
and mortality involved, percutaneous balloon aortic valvuloplasty is recommended in children and
adolescents with catheterization peak LV-to-peak aortic gradient ~50 mm Hg or if they are [32]:
• symptomatic with angina, syncope or dyspnea on exertion (Class I);
• asymptomatic but developed ST/T-wave changes on ECG at rest or with exercise (Class I);
• asymptomatic but have a catheterization peak LV-to-peak aortic gradient > 60 mm Hg (Class I);
• asymptomatic but want to play competitive sports (Class II)
7.5.2. Medical Management
Prophylaxis against infective endocarditis is not recommended for VAS by the Guidelines from
AHA except for prosthetic valve in aortic position [55]. The VAS is a progressive disorder and may
be associated with exercise-induced sudden death in those who have moderate to severe obstruction.
ACC/AHA Task Force 2 as well as Task Force 4 recommendation for participation in sports and physical
exercise are the following: mild VAS with peak-to-peak catheter gradient of <30 mm Hg (Doppler mean
gradient <25 mm Hg and peak gradient <40 mm Hg), moderate VAS with peak-to-peak catheter gradient
from 30 to 50 mm Hg (Doppler mean gradient from 25 to 40 mm Hg and peak gradient from 40 to
70 mm Hg) and severe VAS with peak-to-peak catheter gradient of >50 mm Hg (Doppler mean gradient
>40 mmHg and peak gradient >70 mm Hg) [56,57]. Those with moderate VAS should be evaluated at
least yearly by two-dimensional and Doppler echocardiography, exercise testing and ambulatory ECG.
They can participate in low static/low-to-moderate dynamic and moderate static/low-to-moderate
dynamic competitive sports if they have mild or no LV hypertrophy by echocardiography, absence
of LV strain pattern on the ECG and normal exercise test with normal blood pressure response and
have no symptoms. Those with severe VAS should be followed up closely and should not participate
in competitive sports [34]. Delaying intervention in these patients may not be advantageous [10].
For children and adolescents with residual moderate or severe stenosis, the recommendations for
follow-up and participation in sports are same as those for untreated patients [56,57].
8. Prognosis
In the Second Natural History Study [22], 40% of medically managed patients subsequently
required surgical intervention, whereas almost 40% of the operated patients required a second operation.
Most patients after successful balloon valvuloplasty or surgery remain in New York Heart Association
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Class I but an incidence of sudden death has been reported, mostly in those with residual lesions
or endocarditis.
The results of surgical repair of VAS in pediatric patients is generally excellent, especially if no
patches are involved. The primary repair of VAS with bicuspid aortic valve has enduring results up to
10 years. Those who had balloon valvuloplasty may require repeat catheter intervention or surgical
intervention in significant number of patients with VAS or mixed lesions. Intervention remains the
main modality of the management. Although gene mutations polymorphism and cellular signaling
pathway have been implicated in malformations of valves, none has been confirmed to play central
role that restricts the clinical translational applications at the current time.
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